Zobrazit více v PubMed
Liakina V., Blach S., Terrault N.A., Tacke F., Gamkrelidze I., Craxi A., Tanaka J., Waked I., Dore G.J., Abbas Z., et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study. Lancet Gastroenterol. Hepatol. 2022;7:396–415. doi: 10.1016/S2468-1253(21)00472-6.
PubMed
DOI
Frankova S., Urbanek P., Husa P., Nemecek V., Razavi H., Razavi-Shearer D., Chlibek R., Sperl J. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden. Cent. Eur. J. Public Health. 2019;27:93–98. doi: 10.21101/cejph.a5350.
PubMed
DOI
Chlibek R., Smetana J., Sosovickova R., Gal P., Dite P., Stepanova V., Pliskova L., Plisek S. Prevalence of hepatitis C virus in adult population in the Czech Republic—Time for birth cohort screening. PLoS ONE. 2017;12:e0175525. doi: 10.1371/journal.pone.0175525.
PubMed
DOI
PMC
Chomynová P., Grohmannová K., Dvoráková Z., Cerníková T., Orlíková B., Rous Z., Jarosíková H., Franková H., Dékány L., Fidesová H., et al. Zpráva o Nelegálních Drogách v Ceské Republice 2022. [(accessed on 31 December 2022)]. Available online: https://www.drogy-info.cz/data/obj_files/33774/1171/Zprava_o_nelegalnich_drogach_v_CR_2022_v02_rev221207.pdf.
Degenhardt L., Peacock A., Colledge S., Leung J., Grebely J., Vickerman P., Stone J., Cunningham E.B., Trickey A., Dumchev K., et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. Lancet Glob. Health. 2017;5:e1192–e1207. doi: 10.1016/S2214-109X(17)30375-3.
PubMed
DOI
PMC
Edlin B.R. Perspective: Test and treat this silent killer. Nature. 2011;474:S18–S19. doi: 10.1038/474S18a.
PubMed
DOI
PMC
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) ECDC and EMCDDA Guidance: Prevention and Control of Infectious Diseases among People Who Inject Drugs. [(accessed on 26 December 2022)]. Available online: https://www.emcdda.europa.eu/publications/ecdc-emcdda-guidance_en.
Rolls D.A., Daraganova G., Sacks-Davis R., Hellard M., Jenkinson R., McBryde E., Pattison P.E., Robins G.L. Modelling hepatitis C transmission over a social network of injecting drug users. J. Biol. 2012;297:73–87. doi: 10.1016/j.jtbi.2011.12.008.
PubMed
DOI
Mehta S.H., Genberg B.L., Astemborski J., Kavasery R., Kirk G.D., Vlahov D., Strathdee S.A., Thomas D.L. Limited uptake of hepatitis C treatment among injection drug users. J. Community Health. 2008;33:126–133. doi: 10.1007/s10900-007-9083-3.
PubMed
DOI
PMC
Macias J., Morano L.E., Tellez F., Granados R., Rivero-Juarez A., Palacios R., Rios M., Merino D., Perez-Perez M., Collado A., et al. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. J. Hepatol. 2019;71:45–51. doi: 10.1016/j.jhep.2019.02.018.
PubMed
DOI
Frankova S., Jandova Z., Jinochova G., Kreidlova M., Merta D., Sperl J. Therapy of chronic hepatitis C in people who inject drugs: Focus on adherence. Harm Reduct J. 2021;18:69. doi: 10.1186/s12954-021-00519-y.
PubMed
DOI
PMC
European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol. 2020;73:1170–1218. doi: 10.1016/j.jhep.2020.08.018.
PubMed
DOI
Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J. Hepatol. 2001;34:730–739. doi: 10.1016/S0168-8278(00)00097-0.
PubMed
DOI
Bochud P.Y., Cai T., Overbeck K., Bochud M., Dufour J.F., Mullhaupt B., Borovicka J., Heim M., Moradpour D., Cerny A., et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J. Hepatol. 2009;51:655–666. doi: 10.1016/j.jhep.2009.05.016.
PubMed
DOI
Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–293. doi: 10.1002/hep.510240201.
PubMed
DOI
European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J. Hepatol. 2018;69:154–181. doi: 10.1016/j.jhep.2018.03.018.
PubMed
DOI
European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018;69:182–236. doi: 10.1016/j.jhep.2018.03.019.
PubMed
DOI
Rosenthal E.S., Silk R., Mathur P., Gross C., Eyasu R., Nussdorf L., Hill K., Brokus C., D’Amore A., Sidique N., et al. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. Clin. Infect. Dis. 2020;71:1715–1722. doi: 10.1093/cid/ciaa105.
PubMed
DOI
PMC
Grebely J., Dalgard O., Conway B., Cunningham E.B., Bruggmann P., Hajarizadeh B., Amin J., Bruneau J., Hellard M., Litwin A.H., et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol. Hepatol. 2018;3:153–161. doi: 10.1016/S2468-1253(17)30404-1.
PubMed
DOI
Dore G.J., Altice F., Litwin A.H., Dalgard O., Gane E.J., Shibolet O., Luetkemeyer A., Nahass R., Peng C.Y., Conway B., et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann. Intern. Med. 2016;165:625–634. doi: 10.7326/M16-0816.
PubMed
DOI
Kaberg M., Edgren E., Hammarberg A., Weiland O. Hepatitis C virus (HCV) related liver fibrosis in people who inject drugs (PWID) at the Stockholm Needle Exchange—Evaluated with liver elasticity. Scand. J. Gastroenterol. 2019;54:319–327. doi: 10.1080/00365521.2019.1580764.
PubMed
DOI
Pradat P., Voirin N., Tillmann H.L., Chevallier M., Trepo C. Progression to cirrhosis in hepatitis C patients: An age-dependent process. Liver Int. 2007;27:335–339. doi: 10.1111/j.1478-3231.2006.01430.x.
PubMed
DOI
Feld J.J., Liang T.J. Hepatitis C—Identifying patients with progressive liver injury. Hepatology. 2006;43:S194–S206. doi: 10.1002/hep.21065.
PubMed
DOI
Llamosas-Falcon L., Shield K.D., Gelovany M., Hasan O.S.M., Manthey J., Monteiro M., Walsh N., Rehm J. Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis. J. Hepatol. 2021;75:536–546. doi: 10.1016/j.jhep.2021.04.018.
PubMed
DOI
Broz J., Malinovska J., Nunes M.A., Kucera K., Rozekova K., Zejglicova K., Urbanova J., Jensovsky M., Brabec M., Lustigova M. Prevalence of diabetes and prediabetes and its risk factors in adults aged 25-64 in the Czech Republic: A cross-sectional study. Diabetes Res. Clin. Pract. 2020;170:108470. doi: 10.1016/j.diabres.2020.108470.
PubMed
DOI
Migdal A.L., Jagannathan R., Qayed E., Cusi K., McCoy R.G., Pasquel F.J., Miller L.S. Association of Obesity, Diabetes, and Alcohol Use With Liver Fibrosis Among US Adults With Hepatitis C Virus Infection. JAMA Netw. Open. 2022;5:e2142282. doi: 10.1001/jamanetworkopen.2021.42282.
PubMed
DOI
PMC
Manza P., Kroll D., McPherson K.L., Johnson A., Dennis E., Hu L., Tai B., Volkow N.D. Sex differences in weight gain during medication-based treatment for opioid use disorder: A meta-analysis and retrospective analysis of clinical trial data. Drug Alcohol. Depend. 2022;238:109575. doi: 10.1016/j.drugalcdep.2022.109575.
PubMed
DOI
PMC
Baykara S., Alban K. The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients. Psychiatry Res. 2019;272:450–453. doi: 10.1016/j.psychres.2018.12.153.
PubMed
DOI
Mahboub N., Honein-AbouHaidar G., Rizk R., de Vries N. People who use drugs in rehabilitation, from chaos to discipline: Advantages and pitfalls: A qualitative study. PLoS ONE. 2021;16:e0245346. doi: 10.1371/journal.pone.0245346.
PubMed
DOI
PMC
Olafsson S., Tyrfingsson T., Runarsdottir V., Bergmann O.M., Hansdottir I., Bjornsson E.S., Johannsson B., Sigurdardottir B., Fridriksdottir R.H., Love A., et al. Treatment as Prevention for Hepatitis C (TraP Hep C)—A nationwide elimination programme in Iceland using direct-acting antiviral agents. J. Intern. Med. 2018;283:500–507. doi: 10.1111/joim.12740.
PubMed
DOI
Olafsson S., Fridriksdottir R.H., Love T.J., Tyrfingsson T., Runarsdottir V., Hansdottir I., Bergmann O.M., Bjornsson E.S., Johannsson B., Sigurdardottir B., et al. Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: A population-based study. Lancet Gastroenterol. Hepatol. 2021;6:628–637. doi: 10.1016/S2468-1253(21)00137-0.
PubMed
DOI
Rossi C., Butt Z.A., Wong S., Buxton J.A., Islam N., Yu A., Darvishian M., Gilbert M., Wong J., Chapinal N., et al. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort. J. Hepatol. 2018;69:1007–1014. doi: 10.1016/j.jhep.2018.07.025.
PubMed
DOI
Johannesson J.M., Fridriksdottir R.H., Love T.J., Runarsdottir V., Hansdottir I., Love A., Thordardottir M., Hernandez U.B., Olafsson S., Gottfredsson M., et al. High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results From the TraP Hep C Program-A Prospective Nationwide, Population-Based Study. Clin. Infect. Dis. 2022;75:1732–1739. doi: 10.1093/cid/ciac272.
PubMed
DOI
PMC
Platt L., Minozzi S., Reed J., Vickerman P., Hagan H., French C., Jordan A., Degenhardt L., Hope V., Hutchinson S., et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst. Rev. 2017;9:CD012021. doi: 10.1002/14651858.CD012021.pub2.
PubMed
DOI
PMC
WHO Global Hepatitis Report. 2017. [(accessed on 31 December 2022)]. Available online: https://www.who.int/publications/i/item/9789241565455.
Moreno G.A., Wang A., Sanchez Gonzalez Y., Diaz Espinosa O., Vania D.K., Edlin B.R., Brookmeyer R. Value of Comprehensive HCV Treatment among Vulnerable, High-Risk Populations. Value Health. 2017;20:736–744. doi: 10.1016/j.jval.2017.01.015.
PubMed
DOI
Skoupa J., Urbanek P. A comparison of cost-effectiveness analysis of two strategies—Immediate and delayed initiation of treatment of chronic hepatitis C in the Czech Republic. Gastroent Hepatol. 2018;72:58–64. doi: 10.14735/amgh201858.
DOI
Flisiak R., Zarebska-Michaluk D., Ciupkeviciene E., Drazilova S., Frankova S., Grgurevic I., Hunyady B., Jarcuska P., Kupcinskas L., Makara M., et al. HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons. Viruses. 2022;14:482. doi: 10.3390/v14030482.
PubMed
DOI
PMC
Wolf E., Rich N.E., Marrero J.A., Parikh N.D., Singal A.G. Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis. Hepatology. 2021;73:713–725. doi: 10.1002/hep.31309.
PubMed
DOI
PMC